Related Experiment Video
Updated: Sep 29, 2026

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021
Cefuroxime treatment of bacterial meningitis in infants and children
Abstract:
Recently, ampicillin- and chloramphenicol-resistant strains of Haemophilus influenzae type b and multiply-resistant Salmonella strains have appeared in some areas of the world. Therefore, alternative drug therapy for infections caused by these organisms is being sought. We used cefuroxime to successfully treat five children with H. influenzae type b meningitis and two children with Salmonella meningitis. Four H. influenzae type b isolates and one Salmonella isolate were resistant to ampicillin, chloramphenicol, and cotrimoxazole. Each of the patients received 200 to 250 mg of cefuroxime per kg per day in four divided doses for 14 to 21 days. The concentrations of cefuroxime in cerebrospinal fluid at 2 h after intravenous 50-mg/kg doses were 6.4 +/- 1.7 (mean +/- standard deviation) and 3.6 +/- 2.2 micrograms/ml on days 2 and 14 of treatment, respectively. The level of drug in cerebrospinal fluid was 1.34 +/- 1.3 micrograms/ml in children without meningitis. The mean cefuroxime concentration in subdural fluid samples from each of three patients was 12.6, 15, and 25.2 micrograms/ml. Cefuroxime is recommended as an alternative drug for the treatment of H. influenzae type b meningitis, but additional information is necessary before cefuroxime can be recommended for therapy of Salmonella meningitis.
Insights
Cefuroxime effectively treated meningitis caused by drug-resistant Haemophilus influenzae type b and Salmonella strains in children. This antibiotic shows promise as an alternative therapy for these serious infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Background:
- Emergence of ampicillin- and chloramphenicol-resistant Haemophilus influenzae type b and multiply-resistant Salmonella strains necessitates alternative treatments.
- Bacterial meningitis remains a significant global health concern, particularly in pediatric populations.
Purpose of the Study:
- To evaluate the efficacy and safety of cefuroxime in treating pediatric meningitis caused by antibiotic-resistant bacteria.
- To determine cefuroxime concentrations in cerebrospinal fluid and subdural fluid during treatment.
Main Methods:
- Clinical case series involving seven children diagnosed with meningitis.
- Treatment with cefuroxime at 200-250 mg/kg/day in four divided doses for 14-21 days.
- Measurement of cefuroxime levels in cerebrospinal fluid and subdural fluid.
Main Results:
- Successful treatment outcomes were observed in all five children with H. influenzae type b meningitis and two children with Salmonella meningitis.
- Cefuroxime achieved therapeutic concentrations in cerebrospinal fluid, exceeding levels in non-meningitis patients.
- Adequate cefuroxime concentrations were also found in subdural fluid samples.
Conclusions:
- Cefuroxime is a recommended alternative therapy for meningitis caused by H. influenzae type b, especially resistant strains.
- Further research is needed to establish cefuroxime's role in treating Salmonella meningitis.
More Related Videos
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Dosing: Infants and Children
Rocky Mountain Spotted Fever
Bacterial Meningitis
Viral Meningitis
Bacterial Meningitis I: Introduction

